Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis | Zendy

Allan L. Klein | Zendy; Massimo Imazio | Zendy; Paul Cremer | Zendy; Antonio Brucato | Zendy; Antonio Abbate | Zendy; Fang Fang | Zendy; Antonella Insalaco | Zendy; Martin M. LeWinter | Zendy; Basil S. Lewis | Zendy; David Lin | Zendy; Sushil Allen Luis | Zendy; Stephen J. Nicholls | Zendy; Arian Pano | Zendy; Alistair Wheeler | Zendy; John F. Paolini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis

Author(s) -

Allan L. Klein,

Massimo Imazio,

Paul Cremer,

Antonio Brucato,

Antonio Abbate,

Fang Fang,

Antonella Insalaco,

Martin M. LeWinter,

Basil S. Lewis,

David Lin,

Sushil Allen Luis,

Stephen J. Nicholls,

Arian Pano,

Alistair Wheeler,

John F. Paolini

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2027892

Subject(s) - trap (plumbing) , pericarditis , medicine , environmental science , environmental engineering

Interleukin-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine trap, were studied previously in a phase 2 trial involving patients with recurrent pericarditis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research